

YARI CIRIBILLI, PhD

BIRTH-DATE:

BIRTH-PLACE:

ADDRESS:

TELEPHONE:

E-MAIL: yari.ciribilli@unitn.it,

CITIZENSHIP: Italian

CIVIL STATUS:

KNOWN LANGUAGES: English (First Certificate in English, ESOL - Uni
German (very basic)

ORCID: 0000-0001-9231-379X

EDUCATIONAL STUDIES:

- August 2010: Enrollment to the National Order of Biologists
- 1 January 2006 – 31 December 2008: PhD program student (XXI° Cycle) in Oncological Genetics and Biology of Differentiation at Biomedical Science and Technology School - University of Genoa; (Project title: Transcriptional cooperation between p53 and Estrogen Receptors at a polymorphic variant of the VEGFR-1 (Flt-1) promoter – Tutors: Dr. A. Inga and Dr. G. Fronza)
- 16 June 2002: Professional qualification of Biologist
- 1 October 1996 – 20 February 2002: University Degree “cum laudae” in Biological Sciences at University of Genoa (Thesis title: Characterization of the dominant negative potential of mutants of the tumor suppressor gene p53 using a yeast-based assay – Advisors: Prof. A. Abbondandolo, Dr. G. Fronza)
- August 1996: General Certificate of Education at “Leonardo da Vinci” Scientific High School of Genoa

PROFESSIONAL EXPERIENCES:

- 16 December 2022 – to date: Associate Professor in Genetics and Group Leader of the Laboratory of Molecular Cancer Genetics, CIBIO Department - University of Trento, Italy
- 16 December 2019 – to 15 December 2022: Tenured Assistant Professor and Group Leader of the Laboratory of Molecular Cancer Genetics, CIBIO Department – Univ of Trento, Italy
- 3 November 2014 – 15 December 2019: Assistant Professor and Group Leader of the Laboratory of Molecular Cancer Genetics, Centre for Integrative Biology (CIBIO) - University of Trento, Italy
- 1 May 2013 – 2 November 2014: PostDoctoral Fellow at Laboratory of Transcriptional Networks, Centre for Integrative Biology (CIBIO) - University of Trento, Italy
- 1 May 2010 – to 30 April 2013: Marie Curie Action – PAT PostDoc Fellow at Laboratory of Transcriptional Networks, Centre for Integrative Biology (CIBIO) - University of Trento, Italy
- 1 June 2009 to 30 April 2010: PostDoc Researcher Fellow, Molecular Mutagenesis and DNA Repair Laboratory at National Institute for Cancer Research (IST), Genoa, Italy
- 12 January 2009 – 31 May 2009: PostDoc Fellow at Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM) – Biopark, Regensburg, Germany
- 1 October 2008 – 23 December 2008: Visiting Fellow during the PhD program at Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM) – Biopark, Regensburg, Germany
- 5 May 2008 – 30 September 2008: Visiting Fellow during the PhD program at Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM) – Hannover, Germany
- 4 February 2008 – to 4 May 2008: Visiting Fellow during the PhD program at Laboratory of Transcriptional Networks, Centre for Integrative Biology (CIBIO) - University of Trento, Italy
- 16 April 2007 – 9 July 2007: Visiting Fellow during the PhD program at Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM) – Hannover, Germany
- 1 January 2006 – 31 December 2008: PhD program (XXI° Cycle) in Oncological Genetics and Biology of Differentiation at Biomedical Science and Technology School - University of Genoa, winner of a Fellowship issued by University of Genoa, Italy

- 1 January 2003 – 31 December 2005: Graduate Fellow, Mutagenesis Laboratory of National Institute for Cancer Research (IST), Genoa, Italy, winner of a National Fellowship issued by Italian Foundation for Cancer Research (FIRC)
- July 2002 – 31 December 2002: Collaboration with the same Laboratory as junior researcher
- 10 April 2002 – 10 June 2002: Collaboration with the same Laboratory due to an assignment of a temporary researcher position
- 1 October 2000 - 20 February 2002: Undergraduate Internship for the preparation of the experimental thesis, Mutagenesis Laboratory of National Institute for Cancer Research (IST), Genoa, Italy

TEACHING EXPERIENCES

A) Undergraduate teaching:

- September 2023 to date: Part of the course in Genetics, Bachelor of Science in Biomolecular Sciences and Technology, University of Trento, Italy
- September 2019 to date: “Introduction to Cancer Biology”, Bachelor of Science in Biomolecular Sciences and Technology, University of Trento, Italy
- February 2019 to date: Cancer Biology, Master of Science in Cellular and Molecular Biotechnology, University of Trento, Italy
- September 2015 to January 2019: Cancer Genetics, Master of Science in Cellular and Molecular Biotechnology, University of Trento, Italy
- February 2015: Molecular Cancer Genetics, Bachelor of Science in Biomolecular Sciences and Technology, Univ. of Trento
- February 2015: Genetics, - PAS, University of Trento, Italy
- February 2014: Laboratory of Cellular Biology, Istituto De Carneri, Civezzano (TN), Italy
- Autumn 2012: Laboratory of Single Gene Diseases, Master of Science in Cellular and Molecular Biotechnology, University of Trento, Italy
- Spring 2010 to date: Laboratory of Genetics, Bachelor of Science in Biomolecular Sciences and Technology, University of Trento, Italy

B) Student Supervision from independence:

- **Bachelor of Science:** 18 students (2 currently)
- **Master of Science:** 24 students (1 currently)
- **Supervision of ERASMUS students:** 2 students
- **Supervision of PhD Candidates:** 6 students (1 currently)

AWARDS-GRANTS:

- 2010: Winner of a co-funding incoming PostDoc grant issued by Marie Curie Action – Autonomous Province of Trento (PAT) for the three-year period 2010-2013.
- 2009: Winner of a PostDoc short-term fellowship issued by Bavaria Fraunhofer Society.
- 2008: Winner of a Meeting bursary issued by European Association for Cancer Research (EACR) to participate at ECCO 20 meeting in Lyon, France.
- 2004: Winner of a Meeting bursary issued by Fondazione Adriano Buzzati-Traverso to participate at VI° Convegno FISV, Riva del Garda, Italy.
- 2002: Winner of a National Fellowship issued by Italian Foundation for Cancer Research (FIRC).

COLLABORATIONS

- Prof. Juergen Borlak (Centre for Pharmacology and Toxicology, Hannover, Germany);
- Dr. Mattia Barbareschi (Unit of Surgical Pathology, Trentino BioBank, Santa Chiara Hospital, Trento, Italy);
- Dr. Antonella Ferro (Unit of Medical Oncology, Santa Chiara Hospital, Trento, Italy);
- Dr. Michael A. Resnick (NIEHS, NIH, Research Triangle Park, NC, USA);
- Dr. Gilberto Fronza (Mutagenesis Unit, Natl. Inst. For Cancer Research –IST-, Genoa, Italy);

- Dr. Daniel Menendez (Chromosome Stability Group, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA);
- Dr. Jean-Christophe Bourdon (University of Dundee, Scotland, UK);
- Prof. Daniele Bergamaschi (Blizard Institute, Barts and The London School of Medicine, UK);
- Dr. Annette Paschen (UniKlinikum Essen, Germany);
- Prof. Galina Selivanova (Karolinska Institutet, Stockholm, Sweden);
- Prof. Silvio Biccato (University of Modena and Reggio Emilia, Italy);
- Dr. Neda Slade (Ruder Boskovic Institute, Zagreb, Croatia);
- Prof. Stefano Indraccolo (Istituto Oncologico Veneto, Padoa, Italy);
- Dr. Ira-Ida Skvortsova (Medical University of Innsbruck, Austria);
- Prof. Daiva Baltriukienė (Life Sciences Center, Vilnius University, Lithuania);
- Dr. Eva Martinez-Balibrea (Catalan Institute of Oncology, Badalona, Spain);
- Dr. Colinda Scheele (VIB-KU Leuven Center for Cancer Biology, Belgium);
- Dr. Joanna Zawacka-Pancau (Karolinska Institutet, Stockholm, Sweden);
- Prof. Asma Omezzine (University of Monastir, Tunisia).

PUBLICATIONS:

H-index = 22 - * = equal contribution

Last/Corresponding Author Full Papers

1. Ferro A, Generali D, Caffo O, Caldara A, De Lisi D, Dipasquale M, Lorenzi M, Monteverdi S, Fedele P, **Ciribilli Y**. Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? *Semin Oncol*. 2023 Jun-Oct;50(3-5):90-101. doi: 10.1053/j.seminoncol.2023.08.002. Epub 2023 Aug 26.
2. Meškytė EM, Pezzè L, Bartolomei L, Forcato M, Bocci IA, Bertalot G, Barbareschi M, Oliveira-Ferrer L, Bisio A, Biccato S, Baltriukienė D, **Ciribilli Y**. ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1/NF-κB axis. *Cell Death Dis*. 2023 Apr 12;14(4):263.
3. Martinez-Balibrea E*, **Ciribilli Y***. Editorial: Transcriptional Regulation as a Key Player in Cancer Cells Drug Resistance *Front Oncol*. 2021 Oct 26;11:764506. eCollection 2021.
4. Tadijan A, Precazzini F, Hanžić N, Radić M, Gavioli N, Vlašić I, Ozretić P, Pinto L, Škreblić L, Barban G, Slade N, **Ciribilli Y**. Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness. *Cancers (Basel)*. 2021 Oct 18;13(20):5231.
5. Pezzè L, Meškytė EM, Forcato M., Pontalti S., Badowska K.A., Rizzotto D., Skvortsova I., Biccato S., **Ciribilli Y**. ETV7 regulates breast cancer stem-like cell plasticity by repressing IFN-response genes. *Cell Death and Disease* (2021) 12:742.
6. Meškytė EM, Keskas S, **Ciribilli Y**. MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis. *Int J Mol Sci*. 2020 Oct 18;21(20):7710. doi: 10.3390/ijms21207710.
7. Alessandrini F, Pezzè L, Menendez D, Resnick MA, **Ciribilli Y**. ETV7-Mediated DNAJC15 Repression Leads to Doxorubicin Resistance in Breast Cancer Cells. *Neoplasia*. 2018 Aug;20(8):857-870.
8. Alessandrini F., Pezzè L., **Ciribilli Y**. LAMPs: Shedding light on cancer biology. *Semin Oncol*. 2017 Aug;44(4):239-253.
9. Bisio A., Zamborszky J., Zaccara S., Lion M., Tebaldi T., Sharma V., Raimondi I., Alessandrini F., **Ciribilli Y***, Inga A.*. Cooperative interactions between p53 and NFκB enhance cell plasticity. *Oncotarget*. 2014 Dec 15;5(23):12111-25.
10. Bisio A., De Sanctis V., Del Vescovo V., Jegga A.G., Denti M.A., Inga A. and **Ciribilli Y**. MiRNA-based, p53 dependent post-transcriptional circuits: mechanisms, targets and inter-individual variation. *BMC Cancer*. 2013 Nov 21;13:552.

First Author Full Papers

11. **Ciribilli Y**., Borlak J. Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma. *Oncotarget*. 2017 Oct 23;8(60):101808-101831.
12. **Ciribilli Y**., Singh P., Inga A., Borlak J. c-Myc targeted regulators of cell metabolism in a transgenic

- mouse model of papillary lung adenocarcinoma. *Oncotarget*. 2016 Oct 4;7(40):65514-65539.
13. **Ciribilli Y.**, Singh P., Spanel R., Inga A., Borlak J. Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas. *Oncotarget*. 2015 Oct 13;6(31):31569-92.
 14. Garritano S.*, Romanel A.*, **Ciribilli Y.***, Bisio A., Gavoci A., Inga A., Demichelis F. *In-silico* identification and functional validation of allele-dependent AR enhancers. *Oncotarget*. 2015 Mar 10;6(7):4816-28.
 15. Monti P.*, **Ciribilli Y.***, Bisio A.*, Foggetti G., Raimondi I., Campomenosi P., Menichini P., Fronza G., Inga A. Δ N-P63 α and TA-P63 α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites. *Oncotarget*. 2014 Apr 30;5(8):2116-30.
 16. Bisio A.*, **Ciribilli Y.***, Fronza G.*, Inga A.*, Monti P.*. P53 mutants in the Tower of Babel of cancer progression. *Human Mutation*. 2014 Jun;35(6):689-701.
 17. **Ciribilli Y.**, Monti P., Bisio A., Nguyen H.T., Ethayathulla A.S., Ramos A., Foggetti G., Menichini P., Menendez D., Resnick M.A., Viadiu H., Fronza G. and Inga A. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code. *Nucleic Acids Res*. 2013 Oct;41(18):8637-53.
 18. Andreotti V.*, **Ciribilli Y.***, Monti P.*, Bisio A., Lion M., Jordan J.J., Fronza G., Menichini P., Resnick M.A. and Inga A. p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-based Screening System. (2011) *PLoS One*. 6(6):e20643. Epub 2011 Jun 2.
 19. **Ciribilli Y***, Andreotti V*, Menendez D*, Schoenfelder G, Resnick MA and Inga A. Complex interplay between p53 and the Estrogen Receptors at a polymorphic variant of the VEGF receptor Flt-1 promoter. (2010) *PLoS One*. 2010 Apr 21;5(4):e10236.
 20. Monti P*, **Ciribilli Y***, Russo D, Bisio A, Perfumo C, Andreotti V, Menichini P, Inga A, Huang X, Gold B, Fronza G. Rev1 and Polzeta influence toxicity and mutagenicity of Me-lex, a sequence selective N3-adenine methylating agent. (2008) *DNA Repair (Amst)*. 7(3):431-8.
 21. Cardellino U.*, **Ciribilli Y.***, Andreotti V. *, Modesto P., Menichini P., Fronza G., Pellegrino C. and Inga A. Transcriptional properties of feline p53 and its tumor-associated mutants: an yeast-based approach. (2007). *Mutagenesis*. 22: 417-23.
 22. Monti P.*, **Ciribilli Y.***, Jordan J., Menichini P., Umbach D.M., Resnick M.A., Luzzatto L., Inga A. and Fronza G. Functionality of germline p53 alleles influences clinical features. (2007). *Clin. Cancer Research*. 13: 3789-95.

Non-First Author Full Papers

23. Fregni M, **Ciribilli Y**, Zawacka-Pancau J. The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer. Accepted *Int J Mol Sci*. 2022
24. Agnusdei V, Minuzzo S, Pinazza M, Gasparini A, Pezzè L, Amaro AA, Pasqualini L, Del Bianco P, Tognon M, Frasson C, Palumbo P, **Ciribilli Y**, Pfeffer U, Carella M, Amadori A, Indraccolo S. Dissecting molecular mechanisms of resistance to Notch1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts. *Haematologica*. 2020 May;105(5):1317-1328. doi: 10.3324/haematol.2019.217687.
25. Monti P, **Ciribilli Y**, Foggetti G, Menichini P, Bisio A, Cappato S, Inga A, Divizia MT, Lerone M, Bocciardi R, Fronza G. P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development. *Biosci Rep*. 2019 Dec 20;39(12). pii: BSR20192114. doi: 10.1042/BSR20192114.
26. Nassiri I, Inga A, Meškytė EM, Alessandrini F, **Ciribilli Y**, Priami C. Regulatory Crosstalk of Doxorubicin, Estradiol and TNF α Combined Treatment in Breast Cancer-derived Cell Lines. *Sci Rep*. 2019 Oct 23;9(1):15172
27. Ozretić P, Hanžić N, Proust B, Sabol M, Trnski D, Radić M, Musani V, **Ciribilli Y**, Milas I, Puljiz Z, Bosnar MH, Levanat S, Slade N. Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines. *Sci Rep*. 2019 Aug 28;9(1):12470.
28. Knezović Florijan M., Ozretić P., Bujak M., Pezzè L., **Ciribilli Y.**, Kaštelan Ž., Slade N., Hudolin T. The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis. *Urol Oncol*. 2019 Sep;37(9):578.e1-578.e10.

29. Bosco B., Defant A., Messina A., Incitti T., Sighel D., Bozza A., **Ciribilli Y.**, Inga A., Casarosa S., Mancini I. Synthesis of 2,6-Diamino-Substituted Purine Derivatives and Evaluation of Cell Cycle Arrest in Breast and Colorectal Cancer Cells. *Molecules*. 2018 Aug 10;23(8).
30. Pinazza M.*, Ghisi M.*, Minuzzo S., Agnusdei V., Fossati G., Ciminale V., Pezzè L., **Ciribilli Y.**, Pilotto G., Venturoli C., Amadori A. and Indraccolo S. Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell Acute Lymphoblastic Leukemia cells. *Oncogene*. 2018. Jul;37(28):3839-3851.
31. Lauria F., Tebaldi T., Lunelli L., Struffi P., Gatto P., Pugliese A., Brigotti M., Montanaro L, **Ciribilli Y.**, Inga A, Quattrone A, Sanguinetti G, Viero G. RiboAbacus: a model trained on polyribosome images predicts ribosome density and translational efficiency from mammalian transcriptomes. *Nucleic Acids Res*. 2015 Dec 15;43(22):e153.
32. Sharma V, Jordan JJ, **Ciribilli Y.**, Resnick MA, Bisio A, Inga A. Quantitative Analysis of NF- κ B Transactivation Specificity Using a Yeast-Based Functional Assay. *PLoS One*. 2015 Jul 6;10(7):e0130170.
33. Tebaldi T, Zaccara S, Alessandrini F, Bisio A, **Ciribilli Y.**, Inga A. Whole-genome cartography of p53 response elements ranked on transactivation potential. *BMC Genomics*. 2015 Jun 17;16:464.
34. Lion M., Raimondi I., Donati S., Jousson O., **Ciribilli Y.**, Inga A. Evolution of p53 transactivation specificity through the lens of a yeast-based functional assay. *PLoS One*. 2015 Feb 10;10(2):e0116177.
35. Zaccara S., Tebaldi T., Pederiva C., **Ciribilli Y.**, Bisio A., Inga A. p53-directed translational control can shape and expand the universe of p53 target genes. *Cell Death and Differentiation*. 2014 Oct;21(10):1522-34.
36. Reamon-Buettner S.M., Sattlegger E., **Ciribilli Y.**, Inga A. and Borlak J. Transcriptional defect of an inherited NKX2-5 haplotype comprising a SNP, a nonsynonymous and a synonymous mutation, associated with human congenital heart disease. *PLoS One*. 2013 Dec 20;8(12):e83295.
37. Leão M., Gomes S., Soares J., Bessa C., Maciel C., **Ciribilli Y.**, Inga A., Pereira C. and Saraiva L. Insights on p53 transcriptional activity in yeast: p53-MDMX regulatory pathway. *FEBS Journal*. 2013 Dec;280(24):6498-507. Epub 2013 Oct 23.
38. Raimondi I., **Ciribilli Y.**, Monti P., Bisio A., Pollegioni L., Fronza G., Inga A. and Campomenosi P. P53 family members modulate the expression of PRODH, but not PRODH2, via intronic p53 response elements. *PLoS One*. 2013 Jul 8;8(7):e69152. Print 2013.
39. Lion M, Bisio A, Tebaldi T, De Sanctis V, Menendez D, Resnick MA, **Ciribilli Y.**, Inga A. Interaction between p53 and estradiol pathways in transcriptional responses to chemotherapeutics. *Cell Cycle*. 2013 Apr 15;12(8):1211-24.
40. Leão M, Pereira C, Bisio A, **Ciribilli Y.**, Paiva AM, Machado N, Palmeira A, Fernandes MX, Sousa E, Pinto M, Inga A, Saraiva L. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. *Biochem Pharmacol*. 2013 May 1;85(9):1234-45.
41. Monti P., Perfumo C., Bisio A., **Ciribilli Y.**, Menichini P., Russo D., Umbach D.M., Resnick M.A., Inga A. and Fronza G. Dominant-negative features of mutant p53 in germline carriers have limited impact on cancer outcomes. (2011) *Mol. Cancer Res*. 9(3):271-9.
42. Reamon-Buettner SM, **Ciribilli Y.**, Traverso I, Kuhls B, Inga A and Borlak J. *HAND1* mutations in septation defects of human hearts. (2009) *Hum Mol Genet*. 18(19):3567-78. Epub 2009 Jul 7.
43. Reamon-Buettner SM, **Ciribilli Y.**, Inga A and Borlak J. A loss-of-function mutation in the binding domain of *HAND1* predicts hypoplasia of the human hearts. (2008) *Hum Mol Genet*. 17(10):1397-405.
44. Monti P., Iannone R., **Ciribilli Y.**, Varadarajan S., Shah D., Menichini P., Gold B. and Fronza G. (2004). Nucleotide Excision Repair defect lethality and mutagenicity induced by Me-lex, a sequence selective N3-adenine methylating agent in absence of Base Excision Repair. *Biochemistry*. 48: 5592-5599.
45. Monti P., Campomenosi P., **Ciribilli Y.**, Aprile A., Inga A., Tada M., Menichini P., Abbondandolo A. and Fronza G. (2003). Characterization of the p53 mutants ability to inhibit p73 β transactivation using a yeast-based functional assay. *Oncogene*. 22: 5252-60.
46. Monti P., Campomenosi P., **Ciribilli Y.**, Iannone R., Inga A., Scott G., Burns P.A., Shah D., Menichini P., Abbondandolo A., Gold B. and Fronza G. (2002). Influences of base excision repair defects on the lethality and mutagenicity induced by Me-lex, a sequence selective N3-adenine methylating agent. *Journal of Biological Chemistry*. 277: 28663-28668.

47. Monti P., Campomenosi P., **Ciribilli Y.**, Iannone R., Inga A., Abbondandolo A., Resnick M.A. and Fronza G. (2002). Tumor p53 mutations exhibit promoter selective dominance over wild type p53. *Oncogene*. 21: 1641-1648.

Book Chapters

Borlak J., **Ciribilli Y.** The Holt-Oram Syndrome and Other Transcription Factor-Related Heart Diseases. Book chapter within <<Muenke M, Kruszka PS, Sable CA, Belmont JW (eds): “Congenital Heart Disease: Molecular Genetics, Principles of Diagnosis and Treatment”. Basel, Karger, 2015, pp 131-144>> following Editor’s invitation.

INVITED or SELECTED TALKS

- ETV7 as a mediator of chemoresistance and cancer aggressiveness in breast cancer. 6th Meeting of the Croatian Association for Cancer Research (HDIR), Zagreb, Croatia, November 10 – 12, 2022
- Understanding the impact of p53 isoforms' expression in human cancer cells. *PathoBiology Group Annual Meeting, Badalona, Spain, October 24-25, 2020*
- A summary of the activities and expertise of the Breast Cancer Research sub-group. *PathoBiology Group-EORTC Spring Meeting, April 26, 2022*
- The novel concept of p53 isoforms. *Tyrolean Cancer Research Institute Seminar, November 19, 2020*
- ETV7 as a novel modulator of transcription influencing cancer stem cells plasticity and response to chemotherapy. *PathoBiology Group Annual Meeting, October 27-28, 2020*
- ETV7 as a novel modulator of transcription influencing cancer stem cells plasticity and response to chemotherapy. *PhD School Seminar, University of Insubria, Varese, Italy, May 06, 2020*
- ETV7 as novel mediator of chemoresistance in breast cancer. *International Conference “CancerMetastasis”, Seefeld-in-Tirol, Austria, December 11 – 14, 2019*
- Impact of p53 isoforms over-expression in human lung cancer cells. *International “p53/p63/p73 family isoforms workshop”, Dubrovnik, Croatia, November 3-6, 2019*
- ETV7 as a mediator of chemoresistance in breast cancer. 24th World Congress in Advanced Oncology, Sparta, Greece, October 10-13, 2019
- Use of innovative models to study cancer biology. *Educational course in Genome and epigenome of human cells, MuSe - Science Museum of Trento, Italy, September 27, 2018*
- ETV7 as novel mediator of chemoresistance in breast cancer. 13th Annual EORTC PathoBiology Group Meeting, Hamburg, Germany, September 9 – 12, 2018
- Novel molecular aspects on the biological functions of the p53 tumor suppressor. *Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST), Meldola (FC), Italy, May 3, 2018*
- p53 isoforms are differentially expressed in human melanomas. *p53 isoforms Conference, Bergen, Norway, June 9 – 12, 2017*
- Identification of novel genes responsible for chemoresistance in breast cancer. 4th Meeting of the Croatian Association for Cancer Research (HDIR), Zagreb, Croatia, November 3 – 5, 2016.
- Role of p53 isoforms in cancer and other pathologies. *Clinical-Scientific Seminar, PhD Course in Translational Medicine in Oncology and Hematology of Genoa, June 2016.*
- p53: novel molecular insights associated with Li-Fraumeni Syndrome. *Educational event, PhD Course in Oncological Genetics and Biology of Differentiation of Genoa, April 2016*
- ΔN-p63α and TA-p63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites. 2nd International p53 Isoforms Workshop, Aix-en-Provence, France, September 20 – 23, 2015.
- Corrupted by TNFalpha-induced signaling: a dark side of wild type p53? *BioDays 2014, Trento, Italy, June 24 – 25, 2014.*
- Decoding the role of p53 family members. *CIBIO Workshop, Trento, December 5-6, 2013.*
- Mutations in the p53 gene family reveal conservation of structure-function in the L1 and L3 loops and a response element code for transcriptional specificity. *American Association for Cancer Research (AACR) 2013 Annual Meeting, Walter E. Washington Convention Center, Washington, DC, USA, April 6 – 10, 2013.*

POSTER PRESENTATION

I presented (or the younger researchers working in my group) more than 40 posters with research data in several national as well as international congresses.

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS

Member of different steering committees a) for the selection of incoming as well as outgoing PostDocs (Science Area Park -Trieste), b) for the evaluation as external reviewer of PhD students' thesis (University of Padoa, Medical School Innsbruck, and Islamabad), c) for the evaluation as internal reviewer of PhD students' yearly progress reports (University of Trento), d) for the selection of meritorious students for the "Collegio di Merito Bernardo Clesio" (University of Trento), a structure that supports students in Trento for the lodging and future abroad internships, and e) for the selection of tutors for the undergrads (University of Trento).

I'm currently the delegate for CIBIO Department for Sports (TOP Sport program) (started in 2015) and for CIBIO bachelor students' internships (started in 2021). I'm also member of the PhD Committee in the International PhD School in Biomolecular Sciences at University of Trento.

Member of the organizing or scientific committee for a) the international "p53/p63/p73 family isoforms workshop", Dubrovnik, Croatia, 3-6 November 2019, b) the "Career Day 2018" and "Career Fair 2019", University of Trento, Italy, March 14th and April 3rd, c) the "PostDoc Research Day, BioDays 2013", University of Trento, Italy, June 3 – 4.

I'm currently serving as Associate Editor for the scientific journals "Frontiers in Oncology" and as Co-Guest Editor for two different special issues that were published in 2021 within the scientific journals "Frontiers in Oncology" (together with Dr. Eva Martinez-Balibrea) and "International Journal of Molecular Sciences" (together with Prof. Paola Bellosta).

I served as reviewer for several respected scientific journals such as Cancer Research, Cell Death & Differentiation, Molecular Cancer Research, Cell Death & Disease, Molecular Oncology, Seminars in Cancer Biology, Scientific Reports, Oncotarget, Oncology Letters, Molecular and Cellular Endocrinology, Journal of Molecular Endocrinology, Molecular Cancer Therapeutics, BBA Gene Regulatory Mechanisms, Cancers, Tumor Biology, Cells, and Current Cancer Drug Targets.

I'm member of National as well as International Scientific Societies, as American Association for Cancer Research (AACR), European Association for Cancer Research (EACR) (I'm also currently serving as "Ambassador" for this International association), Italian Association of Genetics (AGI) and I'm the Chair of the Breast Cancer Subgroup within the European Organization for Research and Treatment of Cancer (EORTC-PBG).

RESEARCH SUPPORT

Ongoing Research Support – Ciribilli (PI)

Italian Ministry of Education – PRIN 2022	Fall 2023 - Fall 2025	Role: Co-PI
New therapeutic strategy for the treatment of ovarian, pancreatic and pleural cancers		
Direct costs: 90,000 Euro		

Completed Research Support – Ciribilli (PI)

Faculty Resources Grant, University of Trento	Fall 2014 - Fall 2022	Role: PI
Study the metastatic potential of reprogrammed MCF7		
Direct cost per year: 25,000 Euro first year, then 10,000		

Bridge Funding, University of Trento	Beginning 2022 - Fall 2022	Role: PI
Direct costs: 13,000 Euro		

Start-up Grant, University of Trento	Fall 2019 – Fall 2021	Role: PI
--------------------------------------	-----------------------	----------

Direct costs: 12,000 Euro

Starting Grant for Young Researchers April 2019 – Dec 2020 Role: PI
Unraveling the role of p53 shorter isoforms in cancer progression and resistance to chemotherapy
Direct costs: 8,900 Euro

Mirai Bio Limited Collaborative Grant, Jun 2017 – Dec 2020 Role: PI
Deciphering the adjuvant effects of novel natural products on chemotherapy efficacy on cancer cells
Direct costs: 12,500 Euro

Merck Speed Grant, Innovation Merck Biopharma Feb 2018 – Feb 2019 Role: PI
Unraveling the role of ETV7 in breast cancer progression and resistance to chemotherapy
Direct cost per year: 10,000 Euro

Completed Research Support – Ciribilli (Senior PostDoc – Project Leader)

Marie Curie – Autonomous Province of Trento (PAT) Co-Fund Grant May 2010 – April 2013
Role: Project Leader
Transcriptional and post-transcriptional circuitries within the tumor suppressor gene p53 network
Direct cost per year: 50,000 Euro

Trento, 21/05/2024

Prof. Yari Ciribilli, PhD
Associate Professor
Laboratory of Molecular Cancer Genetics
Department CIBIO, University of Trento,
Via Sommarive 9, Povo (TN), Italy
+39 (0)461 283173
yari.ciribilli@unitn.it; ciribilli@science.unitn.it